FDA Approves Lucentis Biosimilar Nufymco - Summary - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • Conexiant News Staff

  • January 2, 2026

  • 1 min

Share

Objective:

To announce the FDA approval of Nufymco, a biosimilar of Lucentis, for various ophthalmic conditions.

Approach:
    Key Findings:
    • Nufymco is a biosimilar of Lucentis.
    • FDA approval covers multiple ophthalmic conditions.
    • Zydus Lifesciences will handle marketing in the US.
    Interpretation:

    The approval of Nufymco represents a significant advancement in the availability of affordable treatment options for patients with serious eye conditions, enhancing access to care.

    Conclusion:

    The approval of Nufymco highlights Bioeq's commitment, alongside its partners, to expanding access to high-quality biosimilars in the ophthalmic field.

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by Conexiant News Staff

  • January 2, 2026

Related Content

Editorial: Dynamics of endocrine system dysfunctions and neuro-ophthalmic manifestations: early diagnostic to therapeutic implications

Benchmark for Functional Vision Loss Uncovered in Older Adults

A nationally representative US cohort identified a contrast sensitivity threshold associated with self-reported visual disability.

Diagnosis Gaps Mark Retinopathy Care

A US systematic review found substantial losses across diabetic retinopathy screening, diagnosis awareness, referral, and follow-up.